Results from the PURPOSE 1 trial showed that twice-yearly injections of lenacapavir were superior to once-daily oral Truvada for preventing HIV in cisgender women.
Phase 3 trial data showed that lenacapavir was 100% effective in preventing HIV in cisgender women.
Leave a comment
